BostonGene Corporation Sustainability Profile
BostonGene Corporation, headquartered in the United States, is a pioneering entity in the biotechnology industry, specialising in precision medicine and advanced genomic analysis. Founded in 2017, the company has rapidly established itself as a leader in the development of innovative solutions for cancer treatment, leveraging its proprietary algorithms and comprehensive data analytics. With a focus on personalised healthcare, BostonGene offers unique products and services that integrate genomic data with clinical insights, enabling tailored therapeutic strategies for patients. The company’s commitment to enhancing patient outcomes has garnered recognition within the healthcare community, positioning it as a key player in the evolving landscape of oncology. Through its cutting-edge technology and dedication to research, BostonGene continues to drive advancements in precision medicine, making significant strides in the fight against cancer.
DitchCarbon Score
How does BostonGene Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BostonGene Corporation's score of 30 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
BostonGene Corporation's reported carbon emissions
In 2023, BostonGene Corporation reported total carbon emissions of approximately 259,000,000 kg CO2e from Scope 1 and 2, alongside a significant Scope 3 total of about 6,894,000,000 kg CO2e. This marks an increase in Scope 3 emissions from 6,535,000,000 kg CO2e in 2022 and 6,158,000,000 kg CO2e in 2021, indicating a trend of rising emissions in this category. The Scope 1 and 2 emissions also saw a decrease from 324,000,000 kg CO2e in 2022 and 327,000,000 kg CO2e in 2021. BostonGene has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company does not appear to inherit emissions data from a parent organisation, maintaining its own reporting structure. Overall, while BostonGene Corporation has made strides in tracking its emissions, the lack of defined reduction strategies highlights an area for potential improvement in its climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - |
| Scope 2 | - | - | - | - | - | - | - |
| Scope 3 | 7,410,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is BostonGene Corporation's Industry?
How Carbon Intensive is BostonGene Corporation's Location?
BostonGene Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
BostonGene Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
